Retinal haemangioblastomas in von Hippel–Lindau germline mutation carriers: progression, complications and treatment outcome by Hajjaj, A. (Anass) et al.
Retinal haemangioblastomas in von Hippel–Lindau
germline mutation carriers: progression,
complications and treatment outcome
Anass Hajjaj,1 Koen A. van Overdam,2 Rogier A. Oldenburg,3 Anna E. Koopmans,1
Ans M. W. van den Ouweland,3 Annelies de Klein3 and Emine Kilic1
1Department of Ophthalmology, Erasmus Medical Centre, Rotterdam, the Netherlands
2Department of Vitreoretinal Surgery, The Rotterdam Eye Hospital, Rotterdam, the Netherlands
3Department of Clinical Genetics, Erasmus Medical Centre, Rotterdam, the Netherlands
ABSTRACT.
Purpose: Evaluation of phenotype and treatment outcome of retinal haeman-
gioblastomas (RH) in von Hippel–Lindau (VHL) disease and correlation of these
features with the genotype of VHL germline mutation carriers.
Methods: Retrospective analysis of a longitudinal cohort of 21 VHL germline
mutation carriers and RH. Clinical and genetic data were obtained to analyse the
correlation of genotype with phenotype and treatment outcomes.
Results: All patients were categorized in two genotypic categories: missense
mutations (MM) and truncating mutations (TM). Mean follow-up duration was
16.3 years and did not diﬀer signiﬁcantly between mutation groups (p = 0.383).
Missense mutations (MM) carriers (n = 6) developed more progression-related
complications compared to TM carriers (n = 15) (p = 0.046). Vitreoretinal
surgery was more often applied in MM carriers (p = 0.036). Moderate (visual
acuity (VA)20/80 to 20/200) to severe (VA < 20/200) visual impairment was
observed in 53.3% of the eyes of MM carriers and 28.1% of the eyes of TM
carriers at last recorded visit.
Conclusion: Missense mutations in VHL patients seem to have a higher
prevalence of progression-related complications. Missense mutations (MM)
carriers required therefore more often vitreoretinal surgical treatment with a
worse treatment outcome. Genetic analysis may play a role in determining a pro-
active treatment strategy and prognosis for RH.
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Introduction
Retinal haemangioblastomas (RH) are
benign vascular neoplasms originating in
the neurosensory retina or optic disc.
Retinal haemangioblastomas (RH) can
occur as a solitary tumour or in the
setting of von Hippel–Lindau (VHL)
disease (Online Mendelian Inheritance
inMan 193300), an autosomal dominant
inherited, multisystem neoplastic syn-
drome caused by mutations in the VHL
tumour suppressor gene. Manifestations
of VHL disease include RH, central
nervous system haemangioblastoma,
renal cell carcinoma, phaeochromocy-
toma, pancreatic neuroendocrine
tumours, an endolymphatic sac tumour,
cystadenoma of the epididymis and
broad ligament, and renal and pancreatic
cysts (Lonser et al. 2003). The incidence
of VHL is approximately 1 in 36 000 live
births per year and is highly penetrant, as
90% of the carriers of VHL mutations
develop disease-related symptoms
(Maher et al. 1990). Retinal haeman-
gioblastomas (RH) appear as reddish-
orange vascular lesions in the peripheral
or juxtapapillary regions of the retina
(Fig. 1). The frequency ofRHvaries from
49% to 85% as ocular involvement in
VHLdisease and is the ﬁrstmanifestation
of VHL disease in 43% of patients
(Maher et al. 1990; Singh et al. 2001).
Retinal haemangioblastomas (RH) are
asymptomatic in the early stage of devel-
opment.Vision loss is generally causedby
the exudative aspect of the tumour with
development of hard exudates and retinal
oedema aﬀecting the macula. Further-
more, the larger size of RH can result in
vitreomacular traction and preretinal
ﬁbrotic proliferation. These complica-
tions may lead to exudative and/or trac-
tional retinal detachment (Chew 2005).
Individuals with extended ocular VHL
involvement can develop retinal neovas-
cularization, neovascular glaucoma and
eventually phthisis bulbi. Treatment of
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peripheral RH includes ablative modali-
ties as laser photocoagulation, cryother-
apy, radiation, photodynamic therapy
(PDT) and transpupillary thermotherapy
or radical intervention through vitreo-
retinal surgery (Haddad et al. 2013).
Whether RH will develop progression-
related complications and fail to react to
treatment are yet not well understood.
The VHL tumour suppressor gene is
located on chromosome 3p25.3.2, con-
sists of three exons and encodes the
VHL protein (pVHL) (Latif et al. 1993).
von Hippel–Lindau (VHL) germline
mutations are heterogeneous between
VHL pedigrees and are identiﬁed at all
three exons and splice site regions
(Nordstrom-O’Brien et al. 2010).
Among the targets of pVHL are the
hypoxia-inducible factor 1a (HIF-1a)
and hypoxia-inducible factor 2a (HIF-
2a), which are prolyl-hydroxylated
under normal oxygen conditions. This
allows for binding to pVHL and attach-
ment of ubiquitin peptides, resulting in
proteasomal degradation of HIF-1a
and HIF-2a (Maxwell et al. 1999; Min
et al. 2002). In the absence or dysfunc-
tion of pVHL, HIF-1a and HIF-2a are
not degraded, but form heterodimers
with hypoxia-inducible factor 1b (HIF-
1b) and upregulate proteins promoting
cell proliferation and angiogenesis,
including vascular endothelial growth
factor (VEGF), plasminogen activator
inhibitor-1, erythropoietin (Epo), plate-
let-derived growth factor and trans-
forming growth factor a (Gossage
et al. 2015). These factors have been
hypothesized to contribute in vascular
growth and tumour formation in VHL
disease, including RH (Bohling et al.
1996; Carmeliet et al. 1998; Chan et al.
2007). Genotype–phenotype correla-
tions have been established for further
molecular understanding of the aber-
rant VHL protein function and its
inﬂuence on formation and progression
of RH. Earlier studies show that indi-
viduals with a complete deletion of the
VHL gene may have a signiﬁcantly
decreased risk of developing RH. The
individuals with a complete deletion
that do develop RH have a lower extent
of visual morbidity than patients with
other types of VHL mutations (Chew
2005; Wong et al. 2007; Toy et al. 2012).
Another study showed that the preva-
lence of RH in individuals withmissense
mutations in the functional a-domain of
the VHL gene was signiﬁcantly higher
than for patients with missense muta-
tions in the functional b-domain (Mettu
et al. 2010). Severe ocular involvement,
deﬁned as enucleation of the eye with
ocular VHL disease or phthisical and
prephthisical changes, was likewise cor-
related with having a germline mutation
in previous studies, but did not show a
signiﬁcant association with the muta-
tion type or location (Wong et al. 2007;
Mettu et al. 2010). However, whether a
complicated progression of RH is
related to the genotype of VHL patients
has not yet been investigated. A pro-
gression accompanied by complications
requires a diﬀerent treatment approach
and will possibly lead to diﬀerent treat-
ment outcomes. Therefore, a better
understanding of the complex patho-
physiologic process of RH is essential
for a better treatment strategy. In the
present study, we analysed the correla-
tions between genotypic VHL cate-
gories and tumour progression,
treatment approach and outcome. This
study contributes to a better under-
standing of how VHL gene mutations
aﬀect the progression of RH based on
their presumed eﬀect on pVHL and
their impact on prognosis and may
therefore provide a window for a
patient-tailored treatment approach
and follow-up strategy.
Methods
Patient selection and ascertainment
We conducted a retrospective cohort
study at the Department of Ophthal-
mology of the Erasmus Medical Centre
and the Rotterdam Eye Hospital (Rot-
terdam, the Netherlands). The local
Medical Ethical Committee approved
this study. All data were extracted from
medical records of patients and the
research adhered to the tenets of the
Declaration of Helsinki.
von Hippel–Lindau germline muta-
tion carriers who had an ophthalmo-
logic examination at the Erasmus
Medical Centre or the Rotterdam
Eye Hospital between 1984 and 2017,
and were diagnosed with RH were
included in this study. The diagnosis
of RH was set based on the clinical
appearance of a vasoproliferative reti-
nal tumour with or without the pres-
ence of dilated and tortuous feeder
vessels during fundoscopic examina-
tion with a pharmacologically dilated
pupil. From the 66 conﬁrmed VHL
germline mutation carriers, 30 cases
did have an ophthalmologic examina-
tion elsewhere and were therefore not
included in the study. The electronic
and paper medical records of 36 indi-
viduals from 16 diﬀerent VHL families
were retrospectively reviewed based on
VHL gene mutations reported by the
Department of Clinical Genetics of the
Erasmus Medical Centre. Fifteen of
the 36 VHL germline mutation carri-
ers were excluded from further analy-
sis as they did not develop any ocular
manifestations. We obtained data of
21 patients from 10 families including
sex, age at baseline visit, age at ﬁrst
manifestation of RH during follow-up
and presence of bilateral eye involve-
ment. Furthermore, data on progres-
sion and growth of the tumours and
applied treatment during follow-up
were collected.
Ocular manifestation assessment
A complete ophthalmologic examina-
tion of all patients was performed,
including measurement of the best-
corrected visual acuity (BCVA), slit-
lamp examination and indirect oph-
thalmoscopy. The visual acuity was
categorized into the classiﬁcations of
visual impairment of the World Health
Organization. Mild or no visual
impairment is a BCVA equal to or
better than 20/70. Moderate visual
impairment is considered a BCVA
from 20/80 to 20/200, and severe visual
impairment is deﬁned as a BCVA
worse than 20/200 (Organization
2015). The rating of ocular
Fig. 1. Peripheral retinal haemangioblastoma
with dilated and tortuous feeding vessels,
surrounded by detachment and exudation that
extends into the macula.
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manifestations, their complications and
regression are based on fundus pho-
tographs which have been assessed by
an ophthalmologist. If fundus pho-
tographs were not available, the ocular
manifestations, their complications and
regression were noted based on the
report of the ophthalmologic examina-
tion by an ophthalmologist in the
medical records. The number and loca-
tion of the RH were recorded as well as
the presence of complicated progres-
sion of RH. The exact number of
tumours was not described in the
medical records of two individuals.
However, the records of these patients
did contain the remaining data con-
cerning phenotype, progression and
treatment. All the data of these indi-
viduals are therefore included in the
analysis with the exception of the
number of tumours. The location of
the RH was classiﬁed as peripheral or
juxtapapillary (within one disc diame-
ter from the disc margin). The extent of
peripheral retinal involvement was
described as number of quadrant
involvement of the peripheral retina.
The presence or absence of complica-
tions due to progression of RH, such as
retinal exudation, (extra)macular
oedema, retinal traction, retinal
detachment, preretinal ﬁbrosis, prereti-
nal or vitreous haemorrhage, retinal
neovascularization and neovascular
glaucoma, was noted. Therapy con-
sisted of observation, laser photocoag-
ulation, cryotherapy, transpupillary
thermotherapy, photodynamic ther-
apy, intravitreal anti-VEGF, radiation
therapy, vitreoretinal surgery (subclas-
siﬁed with or without endoresection of
the tumour) or a multiple treatment
approach. Tumour regression was
recorded and the tumour was consid-
ered regressed if at last recorded visit
the size of the tumour decreased with a
change of colour and pigmentation,
and/or if the diameter of the feeding
vessel was reduced. Treatment-related
complications were deﬁned as exuda-
tion, retinal traction, retinal detach-
ment, (extra)macular oedema,
preretinal or vitreous haemorrhage
and preretinal ﬁbrosis within a month
after the procedure according to the
criteria of treatment complications
deﬁned by Kim et al. (2014). Mild
transient haemorrhages and exudation
were not classiﬁed as complications as
these are expected responses to ablative
treatments.
Genotype analysis
The VHL genotype analyses were exe-
cuted as part of general clinical manage-
ment to conﬁrm the diagnosis of VHL
disease, and the resultswere requested for
research purposes. Peripheral blood sam-
ples from every member with clinically
suspected VHL disease of each pedigree
were collected for VHL mutation analy-
sis. Mutational analyses were carried out
at the certiﬁed diagnostic laboratory of
the Department of Clinical Genetics at
the Erasmus University Medical Centre
(certiﬁed by the Dutch Accreditation
Council; EN ISO 15189:2012,M 105) by
Sanger sequencing of the exons and
ﬂanking regions. Copy number analyses
were carried out by multiplex ligation-
dependent probe ampliﬁcation (MLPA)
and ﬂuorescence in situ hybridization
(FISH). Protocols are available upon
request. Mutations were described as
complete deletion, partial deletion, mis-
sense mutation, nonsense mutation,
splice site mutation, duplication and
insertion.
Statistical analysis
IBM SPSS Statistics software version
24.0 was used for statistical analysis.
To compare baseline and clinical char-
acteristics between genotypic categories
as phenotype and the categorized
visual acuity, the Fisher’s exact test
and chi-square test were used for sta-
tistical analysis of categorical data. As
our sample size was less than 30,
continuous data were tested for nor-
mality by the Shapiro–Wilk test. The
independent samples t-test was used to
assess the relationship of the genotypic
categories and age at baseline visit and
age of diagnosis. The Mann–Whitney
U-test and Kruskal–Wallis test were
used for the analysis of the number of
applied treatments as nonparametric
data. The odds ratios were calculated
with their 95% conﬁdence interval. p-
values less than 0.05 were considered to
be statistically signiﬁcant.
Results
VHL germline mutation data
Medical records of 66 individuals with
a known VHL gene germline mutation
were collected and retrospectively anal-
ysed. Thirty-six patients (55%) had an
ophthalmologic examination at the
Erasmus Medical Centre or the Eye
Hospital Rotterdam. The VHL gene
mutation status of the individuals who
underwent an ophthalmic examination
is shown in Table 1. The nomenclature
of the found mutations according to
the Human Genome Variation Society
is shown in Table S1, which shows the
VHL gene mutation status of the anal-
ysed pedigrees on complementary and
genomic DNA level. From the 36
individuals who underwent a complete
ophthalmic examination, a total of 21
patients (58.3%) had evidence of ocu-
lar manifestations of VHL disease
(Fig. S1). For further analyses, the
germline mutation status of these
patients was categorized in two geno-
typic categories, based on their pre-
sumed eﬀect on the VHL protein
structure: signiﬁcant deletions, splice
site mutations, frameshift mutations
and insertions were categorized as the
truncating mutation (TM) group, and
the missense mutations were catego-
rized as missense mutation (MM)
group. The prevalence of RH as man-
ifestation of VHL disease was highest
in individuals with a TM, as 15 of the
22 (68%) individuals developed RH, in
comparison with the patients with a
MM where 6 of the 14 (43%) individ-
uals had ocular involvement of VHL
disease, but did not diﬀer signiﬁcantly
(OR = 2.9; 95% CI: 0.7–11.4,
p = 0.175, chi-squared test).
Ocular manifestations
Demographic data of the included
patients are summarized in Table 2.
Bilateral involvement of ocular VHL
disease was described in 14 of the 21
cases. Ocular VHL disease progressed
severely in three eyes of three patients,
leading to phthisical changes. Two of
the three eyes were enucleated as a
result of the severe involvement. One
TM carrier that had his eye enucleated
underwent the procedure in his ﬁrst
decade, taking into account that some
of the current treatment modalities
were not yet available in that period.
The remaining two individuals with
phthisical changes were MM carriers
and developed structural disruptions
due to ocular VHL disease despite of
application of current treatment
modalities.
The ocular phenotype of VHL
patients was extracted from the medi-
cal records, and we analysed the
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number of RH during follow-up in
either eye. Table 3 summarizes the data
of the ocular phenotype comparing the
genotypic categories. The RH count
was divided into three categories: two
or less, between three and ﬁve RH, and
more than ﬁve RH in either eye. In TM
carriers, the number of RH is small, (6/
13 (46%)) compared MM carriers (1/6
(17%)) with two or less RH develop-
ment during follow-up. Data related to
the number of RH of two TM carriers
were missing and were therefore not
included in the analysis. The rate of
having more than ﬁve RH was higher
in the MM group (50% versus 39%).
Furthermore, the extent of involvement
of the peripheral retina, expressed in
quadrants, was analysed. The majority
of the patients (4/6, 67%) with a MM
had ocular VHL involvement of all
four quadrants, whereas 50.0% (7/14)
of the TM group had an extent of no
more than one quadrant during follow-
up. (Data on the extent of retinal
involvement and location of RH in
one TM carrier were missing). Loca-
tion of RH was divided in the juxta-
papillary and peripheral area. The two
patients who developed RH in the
juxtapapillary region were TM carriers.
We examined ocular complications due
to growth and progression of RH and
compared the complications and clini-
cal characteristics between the geno-
typic categories. The entire MM group
(6/6, 100%) developed complications
due to progression. The most common
complication in this group was vitreo-
retinal traction (5/6, 83%), followed by
preretinal ﬁbrosis (4/6, 67%), neovas-
cularization (4/6, 67%) and subretinal
ﬂuid (4/6, 67%). The TM group had a
lower rate of complication develop-
ment (7/15, 47%). In addition, each
separate complication had a lower rate
in the TM group compared to the MM
group.
Treatment modalities and outcome
Choice for treatment depended on the
location and size of RH and the exist-
ing complications due to progression of
RH. The VHL patients with RH were
most frequently treated with laser pho-
tocoagulation in both genotypic cate-
gories (resp. 100% (6/6) of MM group
versus 93% (14/15) of TM group)
(Table 4). A single treatment method
was not suﬃcient in 62% (13/21) of the
cases. Due to lack of tumour regression
or relapse of tumours in the aﬀected
eye, various treatment modalities were
applied in these patients. Surgical inter-
vention was more often required in
MM carriers, as 83% (5/6) underwent
vitreoretinal surgery, in contrast to TM
carriers of whom only 20% (3/15)
needed surgical treatment. In ﬁve
patients, endoresection of RH during
vitreoretinal surgery was performed. In
this cohort, surgical treatment and
PDT were merely applied if the extent
of ocular VHL disease involved more
than one quadrant and the number of
tumours was three or more in at least
one eye.
Twenty of the 21 patients included in
this study underwent a therapeutic
intervention. One patient was clinically
observed, as his ocular VHL disease
remained stable without the need of
treatment. The six patients with a MM
underwent 63 therapeutic interventions
whereas 14 TM carriers received 116
interventions. The mean ratio of treat-
ment per patient is thus 10.5 treatments
per patient in the MM group versus 8.3
treatments per patient with a TM. The
number of vitreoretinal surgical inter-
ventions was signiﬁcantly higher in
MM carriers (p = 0.036, Mann–Whit-
ney U-test) with a diﬀerence in the ratio
vitreoretinal surgeries per patient of 2.7
in patients with a MM versus 0.9 in
TM carriers (Table 5). Phenotypic
features as number of RH and the
extent of retinal involvement were
analysed regarding the number of
Table 1. Germline mutation status of the von Hippel–Lindau gene of patients with an
ophthalmologic examination (n = 36).
Pedigrees Mutation Expected pVHL change
Individuals with
RH development
Individuals
without RH
development
1 Partial deletion Deletion of exon 1 and 2 1 0
2 Partial deletion Deletion of exon 1 and 2 1 0
3 Deletion p.(Phe76del) 1 0
4 Missense p.(Asn78Ser) 1 0
5 Indel Deletion of exon 2 4 1
6 Deletion Deletion of exon 2 1 0
7 Missense p.(Val130Phe) 5 1
8 Splice site Deletion exon 3 1 0
9 Frameshift p.(Lys159Glufs*15) 5 3
10 Complete deletion VHL gene deletion 1 2
11 Missense p.(Arg167Gln) 0 2
12 Missense p.(Ile151Ser) 0 1
13 Missense p.(Leu89Pro) 0 1
14 Missense p.(Arg64Pro) 0 2
15 Complete deletion VHL gene deletion 0 2
Arg = arginine, Asn = asparagine, del = deletion, fs = frameshift, Glu = glutamic acid,
Gln = glutamine, Ile = isoleucine, Leu = leucine, Lys = Lysine, Phe = phenyalanine,
pVHL = von Hippel–Lindau protein, Pro = proline, RH = retinal haemangioblastoma,
Ser = Serine, Val = valine, VHL = von Hippel–Lindau.
Table 2. Demographics and ocular status of patients with ocular von Hippel–Lindau disease.
Missense
mutation
carriers (n = 6)
Truncating
mutation
carriers (n = 15) p
Sex Male/female 3/3 6/9
Age at baseline
visit (years),
mean  SD
22.4  10.3 26.7  16.4 0.570
Age of diagnosis
RHs (years),
mean  SD
26.1  8.1 25.5  15.5 0.931
Follow-up duration
(years), mean  SD
19.4  7.4 15.1  10.6 0.383
Ocular status, n Unilateral involvement 2 5
Bilateral involvement 4 10
Severe involvement 2 1
4
Acta Ophthalmologica 2020
interventions applied. An increase in
number of RH and extent of retinal
involvement seems to be related to an
increase in application of therapeutic
intervention (p = 0.016 and p = 0.027,
respectively, Kruskal–Wallis test).
Therapeutic complications within a
month after procedure occurred in
28.6% (6/21) of the patients. In both
genotypic categories, three patients
developed therapeutic complications.
The prevalence of therapeutic compli-
cations was highest after PDT. How-
ever, the complications occurred within
a month after treatment in one of the
merely three PDT sessions applied in
this study. The prevalence of compli-
cations after surgical treatment is 29%
(8/28 surgical interventions), followed
by cryotherapy (25%, 4/16 treatments).
No therapeutic complications were
observed in patients with less than a
quadrant retinal involvement or less
than three RH in either eye.
Complete tumour regression at last
recorded visit was observed in 15 of the
21 patients (71%). Regression rate
decreased as the number of RH in
either eye increased (Fig. 2). All
patients with a lower extent of one or
two quadrant retinal involvement had
a complete regression of RH at last
recorded visit. Patients with a compli-
cated progression of RH had a regres-
sion rate of 54% (7/13). As regards the
germline mutation status, the MM
group had a regression rate of 50%
(3/6) versus a rate of 80% in the TM
group (12/15).
Best-corrected visual acuity of the
better- and worse-seeing eye at baseline
and last recorded visit was analysed
and compared between genotypic cat-
egories (Fig. 3). All patients of both
groups had a BCVA equal to or better
than 20/70 in the better-seeing eye at
baseline visit. In the worse-seeing eye,
100% (6/6) of the MM group had mild
or no visual impairment versus 77%
(10/13) of the TM group, respectively.
The BCVA of patients in both geno-
typic groups deteriorated in the better-
seeing eyes, and one patient of the MM
group went from good vision to severe
visual impairment during follow-up.
One patient of the TM group had a
deterioration of visual acuity from a
good vision to moderate visual impair-
ment. At baseline visit, there were
missing data of 3 eyes from patients
with a TM concerning the BCVA. At
ﬁnal visit, no data on the visual acuity
were available of two eyes, one eye of a
patient with a MM, and the other eye
of a patient with a TM, and were
therefore not included in the analysis.
Discussion
This study provides a clinical and genetic
analysis of the progression of retinal
haemangioblastomas in the context of
von Hippel–Lindau disease, the applied
treatments and therapeutic outcomes,
measured in visual function, tumour
regression and therapeutic complica-
tions. Our ﬁndings suggest that MM
carriers develop a higher number of RH
and a greater extent of retinal involve-
ment of ocular VHL disease. This is in
accordance with the earlier genotype–
phenotype correlation study of Dollfus
et al. (2002), who described a statistically
signiﬁcant higher number of RH in
Table 3. Comparison of ocular phenotype in von Hippel–Lindau patients between genotypic
categories.
Missense mutation
carriers
Truncating mutation
carriers
Number
in either eye (%)
≤2 RH 1/6 (16.7) 6/13 (46.2)
3–5 RH 2/6 (33.3) 2/13 (15.4)
>5 RH 3/6 (50.0) 5/13 (38.5)
Quadrant
involvement in
either eye (%)
1 Quadrant 1/6 (16.7) 7/14 (50)
2 Quadrants 1/6 (16.7) 1/14 (7.1)
3 Quadrants 0/6 (0.0) 1/14 (7.1)
All quadrants 4/6 (66.7) 5/14 (35.7)
Location of
RHs in either
eye (%)
Juxtapapillary 0/6 (0.0) 1/14 (7.1)
Peripheral 6/6 (100.0) 12/14 (85.7)
Both 0/6 (0.0) 1/14 (7.1)
Progression-related
complication in
either eye (%)
6/6 (100.0) 7/15 (46.7)
Vitreoretinal traction 5 (83.3) 5 (35.7)
Retinal detachment 3 (50) 3 (21.4)
Haemorrhage 3 (33.3) 3 (21.4)
Exudation 2 (33.3) 3 (21.4)
CME 3 (50.0) 0 (0.0)
Intraretinal oedema 2 (33.3) 3 (21.4)
Subretinal ﬂuid 4 (66.7) 2 (14.3)
Retinal neovascularization 4 (66.7) 1 (7.1)
Neovascular glaucoma 1 (16.7) 1 (7.1)
Preretinal ﬁbrosis 4 (66.7) 3 (21.4)
CME = cystoid macular oedema, RH = retinal haemangioblastomas.
Table 4. Therapeutic modalities applied for retinal haemangioblastomas in patients with von
Hippel–Lindau disease.
Missense
mutation
carriers
(n = 6, %)
Truncating
mutation
(n = 15, %)
Expectative 1 (16.7) 2 (13.3)
Laser photocoagulation 6 (100.0) 14 (93.3)
Cryocoagulation 3 (50.0) 3 (20.0)
Vitreoretinal surgery 5 (83.3) 3 (20.0)
Endoresection 4 (66.7) 1 (6.7)
Photodynamic therapy 2 (33.3) 0 (0.0)
Anti-VEGF 3 (50.0) 3 (20.0)
Radiation therapy Ruthenium-106 brachytherapy 0 (0.0) 1 (6.7)
Multiple treatments 6 (100.0) 7 (46.7)
VEGF = Vascular Endothelial Growth factor.
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patients with a MM. Dolﬀus et al. give a
comprehensive evaluation of the pheno-
type and ocular complications. Compli-
cations as extramacular exudation and
tractional retinal detachment were pre-
sent in 22%of the patients. However, the
ocular complications are not included in
the genotype analysis. Conclusions on
diﬀerent progression of the retinal lesions
between genotypes cannot therefore be
drawn. In the present study, we com-
pared the ocular complications and the
applied treatments between genotypic
categories as an addition to the tradi-
tional genotype–phenotype correlation
studies. This study may therefore be a
ﬁrst step to a personalized follow-up and
treatment approach based on the geno-
type. In our study, progression-related
complications were observed more often
in the MM group compared to the TM
group. The distribution of the partici-
pants into the genotypic categories was
based on the eﬀect of themutation on the
VHL protein (Binderup et al. 2016). We
observed that the prevalence of RH is
highest in VHL patients with a TM,
concurrent with the results observed in a
previous cohort study (Wong et al. 2007),
followed by MM. Phenotypic features
like complicated progression, a high
number of RH and an extensive retinal
involvement are known to complicate the
treatment approach; therefore, standard
ablative treatment will not suﬃce given
the poor success rate and signiﬁcant risks.
Several methods of vitreoretinal
surgery, such as resection of the RH,
can be applied for severe ocular VHL
disease (Schlesinger et al. 2007;
Gaudric et al. 2011). Vitreoretinal
surgery is indicated when RH are
accompanied by complications such as
epiretinal membrane development, vit-
reous haemorrhage, tractional and/or
exudative retinal detachment, prereti-
nal ﬁbrosis or proliferative vitreo-
retinopathy. There is not yet a
standard treatment strategy for RH.
Treatment methods vary depending on
location, size and complications of the
tumour. In addition, current treatment
methods are limited by iatrogenic dam-
age caused to normal eye structures.
Treatment outcomes and complica-
tions due to treatment of RH vary,
and whether RH will respond to treat-
ment is not well understood (Kim et al.
2014; Avci et al. 2017). In our cohort
(Table 4), patients with a MM required
more frequently a radical treatment
approach through vitreoretinal surgery
and multiple treatment modalities than
patients with a TM. Despite a higher
rate of radical treatment approach in
the MM group, regression was more
often achieved in the TM group. How-
ever, visual acuity of the worse eye of
patients with a germline MM remained
stable. Patients with complicated ocu-
lar VHL disease might therefore beneﬁt
from radical treatment as preservation
of visual function. Krzystolik et al.
(2016) described the eﬀectiveness of
pars plana vitrectomy as treatment for
advanced RH development and also
noted a positive eﬀect on improvement
or preservation of visual function in
eyes with complicated RH. The num-
ber of RH seems to be inversely related
to regression rate as an increase in
number is accompanied by a decrease
in regression rate. Therapeutic compli-
cations were merely observed if pro-
gression-related complications were
present. We observed in most cases a
mild and transient course of complica-
tions after treatment with a small
chance of permanently aﬀecting the
visual function. Moderate to severe
visual impairment in at least one eye
was at both baseline and last recorded
visit more prevalent in the MM group.
This analysis shows that patients with a
germline MM have worse therapeutic
and visual outcome and may therefore
require a more frequent follow-up.
Two patients received surgical treat-
ment in an early stage of disease
instead of the more common less inva-
sive treatment modalities as laser pho-
tocoagulation or cryotherapy. These
Table 5. Number of therapeutic interventions applied for retinal haemangioblastomas in patients
with von Hippel–Lindau disease.
Interventions per
patient in missense
group (n = 6)
Interventions per
patient in truncating
group (n = 14) p
Therapeutic interventions,
mean (range)
10.5 (3–22) 7.7 (1–46) 0.080
Laser 4.7 (2–11) 6.0 (1–29) 0.267
Cryocoagulation 1.2 (0–3) 0.7 (0–5) 0.381
Vitreoretinal surgery 2.7 (0–7) 0.9 (0–8) 0.036
Photodynamic therapy 0.5 (0–2) 0.0 (0–0) 0.267
Anti-VEGF 1.5 (0–6) 0.6 (0–5) 0.302
Radiation therapy
(Ruthenium-106 brachytherapy)
0 (0–0) 1 (0–1) 0.850
VEGF = Vascular Endothelial Growth factor.
The bold values are considered statistically signiﬁcant.
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Fig. 2. Line graph showing the regression rate of treated haemangioblastomas relative to the
number of tumours arised during follow-up. In both genotypic categories, the regression rate was
100% if merely one or two tumours arised. Missense mutation carriers showed a faster decrease of
the regression rate when tumour number increased.
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patients needed a smaller number of
interventions than patients who
received surgical intervention in a later
stage of ocular VHL disease. Complete
tumour regression and a good visual
outcome were achieved at last recorded
visit in these patients. However, these
patients had a TM. Removing the
vitreous humour during vitreoretinal
surgery might lead to a reduction of
vitreous-related complication as vitre-
oretinal traction and formation of
ﬁbrosis. These common progression-
related complications in ocular VHL
disease may therefore be prevented
with the expectation of a lesser need
of multiple interventions and a greater
chance of treatment complications.
Treatment through vitreoretinal surgi-
cal intervention in an early stage might
therefore be beneﬁcial for MM carriers
as they seem to have a more compli-
cated progression of ocular VHL dis-
ease (van Overdam et al. 2017).
Truncating mutations most likely
abrogate the VHL protein, or a sub-
stantial structural change of the protein
is expected. Missense mutations are
expected not to result in a gross pVHL
disruption, inﬂuencing one or a few
functions of the VHL protein. Due to
the various impacts on pVHL binding
sites, missense mutations may lead to
diverse tumour aggressiveness and
response to treatment. In renal cell
carcinoma, a lower response rate to
anti-angiogenic treatment is observed
in tumours with a MM, possibly
because of the eﬀect on diverse path-
ways caused by diﬀerent mutation
types. Therefore, targeted therapy for
patients with a MM in the VHL gene
may be more eﬀective (Razaﬁnjatovo
et al. 2016). Our ﬁndings suggest that
such diﬀerence in mutation status
indeed may require a diﬀerent treat-
ment approach in VHL-related RH.
Although this study may be limited
by the relatively small sample size,
which made statistical analysis chal-
lenging, the duration of follow-up with
a mean of 16.3 years is the longest
longitudinal cohort of VHL patients
with RH. This longitudinal analysis
provides a large amount of extended
clinical data of VHL patients giving a
deeper insight into the progression of
RH. Another limitation of this study is
the retrospective aspect as treatment
modalities have improved over time
and the same treatment may lead to
better treatment outcomes nowadays.
The current follow-up guideline has
not been applied to all individuals in
this study as some individuals have
been followed up for 30 years. Signif-
icant progression of ocular disease can
be caused by insuﬃcient treatment or
inadequate follow-up intervals and
therefore lead to dissimilar treatment
strategies and outcomes between VHL
patients with RH. The retrospective
analysis of this study was also limited
by inaccurate recordkeeping, leading to
an incomplete comparison of the lon-
gitudinal data between genotypic
groups.
In conclusion, MM carriers are more
likely to develop more aggressive RH
with progression-related complications,
which consequently leads to a more
radical treatment approach. Treatment
outcomes were worse as less tumour
regression was achieved and a higher
Fig. 3. Bar graph showing the distribution of the initial and last recorded best-corrected visual acuities between genotypic categories. Whereas
missense mutation carriers started with a better visual acuity in best- and worse-seeing eye, at last recorded visit a larger percentage of severe visual
impairment is observed in this genotypic category.
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rate of visual impairment and therapeu-
tic complications was observed. This
study provides data of patients with a
VHL mutation and the development of
RH, and depicts the progression of
ocular VHL disease and the eﬀect of
treatment for each genotypic category.
The observations in this study imply
that genotype analysis may be used as a
tool for determination of treatment
approach and prognosis, and indicate
the importance of genetic counselling
and an ophthalmologic screening pro-
tocol based on genotypic analysis. A
more radical treatment approach in an
early stage of the disease and shorter
follow-up intervals might lead to a
better tumour control in patients with
a genotype possibly leading to a more
progressive phenotype.
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